Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd announced the declaration of voting results for its 53rd Annual General Meeting held on June 23, 2026. All resolutions proposed were duly approved by shareholders with requisite majority. Key approvals include the adoption of standalone and consolidated financial statements for FY26, confirmation of interim and declaration of final dividend, re-appointment of Samir Mehta as Director, and the crucial approval for the issuance of equity shares including convertible bonds/debentures, which passed with 99.93% votes in favor.

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd held its 53rd Annual General Meeting on June 23, 2026, where shareholders approved the Standalone and Consolidated Financial Statements for the fiscal year ended March 31, 2026. The meeting confirmed an interim dividend of ₹29.00 and declared a final dividend of ₹9.00 per equity share for FY26. Significantly, shareholders also approved the issuance of equity shares, including convertible bonds/debentures, providing the company with flexibility for future fundraising. Additionally, Samir Mehta was re-appointed as Director, and the remuneration of cost auditors for 2026-27 was ratified.